UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...